Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Phase I trial of PXD101 begins in patients with hematologic cancer
July 30th, 2004
CuraGen Corp. (CRGN) and TopoTarget, A/S, announced the initiation of a phase I clinical trial to evaluate PXD101, a histone deacetylase (HDAC) inhibitor, in patients with hematologic cancer. Given that PXD101 may play a role as a treatment for hematologic as well as solid cancers, this phase I trial complements the ongoing phase I study in cancer patients with solid tumors initiated in 2003. "We are excited by the initiation of a second phase I for PXD101 as we look to explore the full potential of this promising cancer treatment," stated Timothy M. Shannon, MD, executive vice president of research and development and chief medical officer at...
Source: Genomics & Genetics Weekly (2004-07-30)
|
